WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2016058985) ANYDROUS LIQUID MELATONIN COMPOSITION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2016/058985    International Application No.:    PCT/EP2015/073552
Publication Date: 21.04.2016 International Filing Date: 12.10.2015
Chapter 2 Demand Filed:    08.07.2016    
IPC:
A61K 9/00 (2006.01), A61K 47/10 (2006.01), A61K 47/34 (2006.01)
Applicants: THERAPICON S.R.L. [IT/IT]; Via Malachia Marchesi de Taddei, 21 I-20146 Milano (IT)
Inventors: VERONESI, Paolo Alberto; (IT).
PESCHECHERA, Emanuela; (IT).
VERONESI, Susanna; (IT)
Agent: BIGGI, Cristina; Bugnion S.p.A. Viale Lancetti 17 20158 Milano (IT)
Priority Data:
MI2014A001781 13.10.2014 IT
Title (EN) ANYDROUS LIQUID MELATONIN COMPOSITION
(FR) COMPOSITION DE MÉLATONINE LIQUIDE ANHYDRE
Abstract: front page image
(EN)The present invention relates to a concentrated melatonin solution, wherein melatonin is present in a quantity of 10.0 % or higher in a substantially water-free carrier mixture of ethanol and a polyethoxylated derivative. The concentrated solution, free of preserving agents, is suitable to prepare injectable sterile compositions for parenteral administration, or formulations for topical or oral administration. The invention also encompasses a method for the preparation of the concentrated solution, as well as the possible benefits of the intravenous infusion of high levels of melatonin as adjuvant therapy in Ebola or Dengue hemorrhagic fever (DHF) or as an anti-oxidant/anti-aging treatment.
(FR)La présente invention concerne une solution de mélatonine concentrée, la mélatonine étant présente dans une quantité de 10,0 % ou plus dans un mélange support sensiblement exempt d'eau d'éthanol et d'un dérivé polyéthoxylé. La solution concentrée, exempte d'agents de conservation, est appropriée pour préparer des compositions stériles injectables pour une administration parentérale, ou des formulations pour une administration topique ou orale. L'invention concerne également un procédé pour la préparation de la solution concentrée, ainsi que les avantages possibles de la perfusion intraveineuse de niveaux élevés de mélatonine comme traitement adjuvant de fièvre hémorragique d'Ebola ou de la dengue (DHF) ou comme traitement anti-oxydant/anti-vieillissement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)